Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open; get ready for a slide

May 23, 2018 7:54am

The IBB (-0.26%), XBI (-0.50%), IWM (-0.325) are down while the XLV ain’t saying

Watch, many of the “usual suspects” will be considered oversold

Pre-open indications: 2 BUYs and 1 SELL

If you were a subscriber, and had read Tuesday’s closing “brief” you’d understand how today’s pre-open indications shed light on share pricing!

Get set for a triple-digit loss at the open

Dow futures are DOWN -0.77% (-192 points) and NASDAQ futures are DOWN -0.96% (-67 points)

U.S. stock index futures pointed to a lower open on Wednesday after President Donald Trump told reporters he was not sure whether a scheduled meeting with the North Korean leader Kim Jong Un would actually happen,

European markets retreated amid Italian government uncertainty,

Asian shares declined after Trump's trade comments, with China and Japan leading losses

Data docket: there will be flash manufacturing and services PMIs (purchasing managers' index) at 9:45 a.m. ET and new home sales due at 10 a.m. ET. Later, there will be the release of minutes from the Fed's last meeting.

Today’s indications:

The iShares Nasdaq Biotechnology (IBB) is indicating a DOWNSIDE -0.26% in Wednesday’s pre-market;
The SPDR S&P Biotech ETF (XBI) is indicating a DOWNSIDE of -0.5% in Wednesday’s pre-market;
The Health Care Select Sector SPDR ETF (XLV) is NOT indicating in Wednesday’s pre-open;
The iShares Russell 2000 (IWM) is indicating a DOWNSIDE of -0.32% in Wednesday’s pre-open

Henry’omics:

Wednesday’s moves: sit it out until you understand where momentum is heading

From Tuesday’s night’s newsletter: “a session at the sector’s carnival. The sector experienced a roller-coaster slide at the 10:30 a.m. mark yet continued its cycle to the upside as the downside was top heavy (range of -$0.04 to -$1.84) in 16 equities while the upside ranged (+$0.01 to -$4.40) was better distributed in 27 stocks.”

Guessing the tone and direction of today’s macro market trade and North Korean geopolitical implications sets a questionable tone to the sector.

The lack of event oriented news is a cloud overshadowing the sector.

RISK is still a four letter word, undermining indexes!

A re-cap:

We are half-in for the month of May and the old adage of “sell in May and go away” has weakened as the new month measures sixteen (16) sessions with eleven (11) positive and five (5) negative closes;

In the last five (5) sessions, the iShares NASDAQ Biotechnology (IBB) was down in two and up in three (3) session after Tuesday’s +0.32%, Monday’s -1.32%, Friday’s +0.20%, Thursday’s +0.06% Wednesday’s +0.89% and last Tuesday’s -1.52%;
Tuesday’s decliners ranged from -%0.27 <VYGR -$0.05 > to -7.14% <AST -$0.125> in 16 equities;
Tuesday’s gainers ranged from +0.18% < FATE +$0.02> to +10.80% <ONVO +$0.19 > in 27 equities;

Last five (5) sessions:

Tuesday closed POSITIVE with 16 decliners, 27 advancers and 2 flats;
Monday closed NEGATIVE with 30 decliners, 12 advancers and 3 flat;
Friday closed NEGATIVE with 23 decliners, 22 advancers and o flats;
Thursday closed POSITIVE with 20 decliners, 23 advancers and 2 flats;
Last Wednesday closed POSITIVE with 15 decliners, 27 advancers and 3 flat;

Companies in my headlights:

Cellectis S.A. (CLLS) closed up +$0.87 to $30.56 and has an upside aftermarket indication of +0.21 or +0.69%. CLLS received approval of an amendment to the protocol for the P1 clinical trial of UCART123 for patients with acute myeloid leukemia (AML). In a questionable market, strength and sell signs are evident - SELL;

CRISPR Therapeutics (CRSP) closed down -$0.84 to $63.76 after Monday’s -$0.08 to $64.60 with an upside aftermarket indication of $0.34 or +0.53%. Oversold – Maintaining BUY;

Editas Medicine (EDIT) closed up +$0.78 to $34.16 after Monday’s -$1.47 to $33.38 with an upside aftermarket indication of $0.49 or +1.53. – Maintaining BUY;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.